Analyst Ryan Deschner’s bullish note on Vera Therapeutics (NASDAQ: VERA) sparked a nearly 13% increase in the stock price. The note focused on atacicept, a drug in development for IgA nephropathy, positioning it favorably against competitor Voyxact priced at $30,000 per treatment. Vera may have a competitive advantage pending clinical trial success and regulatory approval.

The Motley Fool Stock Advisor team identified 10 top stocks for investors, excluding Otsuka. Previous recommendations like Netflix and Nvidia saw significant returns, with Stock Advisor boasting a total average return of 1,012%, outperforming the S&P 500. Join Stock Advisor for the latest top 10 list and access an investing community curated for individual investors.

Read more at Yahoo Finance: Why Vera Therapeutics Stock Rocked the Market on Tuesday